Compounds > topotecan
Page last updated: 2024-08-24

topotecan and acetylcysteine

topotecan has been researched along with acetylcysteine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dai, W; Darzynkiewicz, Z; Huang, X; Kurose, A; Tanaka, T; Traganos, F1
Banerji, S; Los, M1
Abd-Ellah, MF; Ahmad, SF; Attia, SM; Bakheet, SA; Hamada, FM1

Reviews

1 review(s) available for topotecan and acetylcysteine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for topotecan and acetylcysteine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.
    Cancer biology & therapy, 2006, Volume: 5, Issue:8

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Fluorescent Antibody Technique; Histones; HL-60 Cells; Humans; Lung Neoplasms; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins

2006
Important differences between topoisomerase-I and -II targeting agents.
    Cancer biology & therapy, 2006, Volume: 5, Issue:8

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Histones; Humans; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins

2006
Germ cell mutagenicity of topoisomerase I inhibitor topotecan detected in the male mouse-dominant lethal study.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2013, Volume: 62

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antineoplastic Agents; Deoxyguanosine; Dose-Response Relationship, Drug; Female; Free Radical Scavengers; Male; Mice; Mutagenicity Tests; Mutagens; Pregnancy; Reactive Oxygen Species; Spermatozoa; Topoisomerase I Inhibitors; Topotecan

2013